KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Receivables (2016 - 2025)

Historic Receivables for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $115.3 million.

  • Pacira BioSciences' Receivables rose 1452.02% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year increase of 1452.02%. This contributed to the annual value of $113.3 million for FY2024, which is 734.02% up from last year.
  • Pacira BioSciences' Receivables amounted to $115.3 million in Q3 2025, which was up 1452.02% from $114.4 million recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Receivables peaked at $115.3 million during Q3 2025, and registered a low of $50.0 million during Q3 2021.
  • Moreover, its 5-year median value for Receivables was $98.4 million (2022), whereas its average is $94.3 million.
  • As far as peak fluctuations go, Pacira BioSciences' Receivables soared by 8703.55% in 2022, and later surged by 119.65% in 2023.
  • Quarter analysis of 5 years shows Pacira BioSciences' Receivables stood at $96.3 million in 2021, then grew by 2.16% to $98.4 million in 2022, then grew by 7.28% to $105.6 million in 2023, then grew by 7.34% to $113.3 million in 2024, then grew by 1.73% to $115.3 million in 2025.
  • Its Receivables stands at $115.3 million for Q3 2025, versus $114.4 million for Q2 2025 and $104.7 million for Q1 2025.